The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer

被引：0
|
作者：
Yang Zhang
Yuanyuan Zeng
Ting Liu
Wenwen Du
Jianjie Zhu
Zeyi Liu
Jian-an Huang
机构：
[1] the First Affiliated Hospital of Soochow University,Department of Respiratory Medicine
[2] Suzhou Key Laboratory for Respiratory Diseases,undefined
[3] Institute of Respiratory Diseases,undefined
[4] Soochow University,undefined
来源：
Respiratory Research | / 20卷
关键词：
PD-L1; EGFR-TKI; Drug resistance; TGF-β/Smad signalling; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
    Shen, Hua
    Wang, Gao-Chan
    Li, Xiang
    Ge, Xin
    Wang, Meng
    Shi, Zhu-Mei
    Bhardwaj, Vikas
    Wang, Zi-Xuan
    Zinner, Ralph G.
    Peiper, Stephen C.
    Aplin, Andrew E.
    Jiang, Bing-Hua
    He, Jun
    ONCOGENE, 2020, 39 (49) : 7181 - 7195
  • [42] EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
    Cansouline, Xavier
    Lipan, Beatrice
    Sizaret, Damien
    Tallet, Anne
    Vandier, Christophe
    Carmier, Delphine
    Legras, Antoine
    CANCERS, 2022, 14 (09)
  • [43] Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
    Lee, Sangah
    Jung, Jiyae
    Lee, Yu-Jin
    Kim, Seon-Kyu
    Kim, Jung-Ae
    Kim, Bo-Kyung
    Park, Kyung Chan
    Kwon, Byoung-Mog
    Han, Dong Cho
    CANCERS, 2021, 13 (12)
  • [44] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    CANCERS, 2019, 11 (07)
  • [45] HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition
    Wang, Qi
    Li, Xuefei
    Ren, Shengxiang
    Su, Chunxia
    Li, Chunyu
    Li, Wei
    Yu, Jia
    Cheng, Ningning
    Zhou, Caicun
    LUNG CANCER, 2020, 147 : 99 - 105
  • [46] Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer
    Liu, Di
    Cao, Ziyang
    Xu, Wen
    Lin, Ge
    Zhou, Xiao
    Ding, Xi
    Wang, Na
    Wu, Chunyan
    Su, Bo
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [47] Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Xia, Jinjing
    Bai, Hao
    Yan, Bo
    Li, Rong
    Shao, Minhua
    Xiong, Liwen
    Han, Baohui
    ONCOTARGET, 2017, 8 (65) : 108522 - 108533
  • [48] Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects
    Cheng, Daoan
    Ge, Kele
    Yao, Xue
    Wang, Banglu
    Chen, Rui
    Zhao, Weiqing
    Fang, Cheng
    Ji, Mei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [49] Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
    Zhou, Juan
    Wang, Jinjing
    Zeng, Yunyun
    Zhang, Xi
    Hu, Qiaoting
    Zheng, Jihua
    Chen, Bei
    Xie, Bo
    Zhang, Wei-Min
    ONCOTARGET, 2015, 6 (42): : 44332 - 44345
  • [50] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
    Martinez-Hernandez, Maria F.
    Lara-Mejia, Luis
    Izquierdo-Tolosa, Carlos
    Cabrera-Miranda, Luis
    Arrieta, Oscar
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12) : 616 - 622
12345